Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor

EU orphan designation number: EU/3/18/2089   
Active ingredient: Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor
Indication: Treatment of Duchenne muscular dystrophy
Sponsor: Dystrogen Therapeutics S.A.
Kasztelanska 49, 60-316 Poznan, Polska

  

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
21/11/2018 Orphan designation (2018)7798 of 19/11/2018